6UF0 Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EDT
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)366.00
Market Cap
€1.02M
Enterprise Value€2.73M
Total Cash (Recent Filing)€37.43K
Total Debt (Recent Filing)€1.27M
Price to Earnings (P/E)―
Beta-1.68
Next Earnings
Nov 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding108,819,870
10 Day Avg. Volume600
30 Day Avg. Volume366
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)-9.40
Price to Sales (P/S)0.00
P/FCF Ratio-6.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Narrowing LossesThe reduction in losses from 2021 indicates some improvement in cost control or operating efficiency, even though profitability has not been reached. If maintained, this trend could reduce future financing needs and extend the company’s ability to pursue development activities.
Lower Cash BurnLower operating and free-cash outflows show that spending has become more controlled than in earlier periods. This does not create self-funding operations, but sustained improvement would preserve liquidity longer and reduce the pace at which additional capital may be required.
Growing Asset BaseThe increase in reported assets provides a larger base than the company held earlier in 2025 and may support ongoing development activities. However, the benefit is limited because the balance sheet remains highly leveraged and assets do not yet offset accumulated equity weakness.
Bears Say
No Revenue BaseThe absence of reported revenue means the business has not demonstrated commercial traction or an operating income stream. Continued dependence on development progress and external financing makes future growth less certain and leaves earnings power unproven over the next several quarters.
Persistent Cash OutflowsOngoing negative operating and free cash flow shows that the company cannot currently fund its activities from internal cash generation. Even with lower burn than in prior years, continued cash consumption can constrain development plans and increase reliance on future financing.
Strained Balance SheetNegative equity and debt greater than total assets indicate significant solvency and credit risk, while limiting financial flexibility. This capital structure can make new funding more difficult or costly and leaves less capacity to absorb setbacks in the company’s development efforts.
NeonMind Biosciences Inc News
6UF0 FAQ
What was NeonMind Biosciences Inc’s price range in the past 12 months?
NeonMind Biosciences Inc lowest stock price was <€0.01 and its highest was €0.04 in the past 12 months.
What is NeonMind Biosciences Inc’s market cap?
NeonMind Biosciences Inc’s market cap is €1.02M.
When is NeonMind Biosciences Inc’s upcoming earnings report date?
NeonMind Biosciences Inc’s upcoming earnings report date is Nov 27, 2026 which is in 46 days.
How were NeonMind Biosciences Inc’s earnings last quarter?
NeonMind Biosciences Inc released its earnings results on Aug 01, 2026. The company reported >-€0.001 earnings per share for the quarter.
Is NeonMind Biosciences Inc overvalued?
According to Wall Street analysts NeonMind Biosciences Inc’s price is currently Overvalued.
Does NeonMind Biosciences Inc pay dividends?
NeonMind Biosciences Inc does not currently pay dividends.
What is NeonMind Biosciences Inc’s EPS estimate?
NeonMind Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeonMind Biosciences Inc have?
NeonMind Biosciences Inc has 108,819,870 shares outstanding.
What happened to NeonMind Biosciences Inc’s price movement after its last earnings report?
NeonMind Biosciences Inc reported an EPS of >-€0.001 in its last earnings report. Following the earnings report the stock price went up 9.524%.
Which hedge fund is a major shareholder of NeonMind Biosciences Inc?
Currently, no hedge funds are holding shares in DE:6UF0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NeonMind Biosciences Inc
Lancaster Resources Inc. focuses on acquiring, exploring, and advancing both mineral deposits and sustainable energy initiatives. A notable asset for the company is its exclusive right to acquire full ownership of the Alkali Flat lithium brine project, located in Lordsburg, New Mexico, in the United States. The firm's headquarters are situated in West Vancouver, Canada.